# Atantares

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atantares

- Industry: Biotechnology
- Headquarters: Suzhou Industrial Park, China
- Website: www.atantares.com/
- Latest round: Series A (Jan 22, 2026)
- Investors on record: 6

## About

Established in 2021 and based in Shanghai, China, Xinsu Technology (Suzhou) Co., Ltd., trading as Atantares, is a biotechnology company that develops molecular microarrays using integrated circuit technology to provide services such as high-throughput synthesis and detection of molecules such as DNA, RNA, and proteins. The company's team comes from MIT, Tsinghua University and other institutions, and Intel, Thermo Fisher and other technology companies, in biotechnology, integrated circuits, MEMS and microfluidics and other aspects of R & D capabilities and DNA synthesis services. The co-founder, Mr. Dan Wu, graduated from MIT Mechanical Department and has independently developed a POC immunoassay platform for detecting sepsis with high throughput and high sensitivity. In January 2026, Atantares raised a series A+ funding from new investors Leader Venture Capital and Zhonggao Capital.

The company utilizes integrated circuit technology to develop molecular chips for high-throughput synthesis and detection of molecules such as DNA, RNA, and proteins. Meanwhile, based on the downward extension of the DNA synthesis platform, the Company utilizes its synthesis process management system and automated instrument development capabilities to further expand into applications such as mRNA drug discovery and single-molecule detection. Among them, based on the high-throughput DNA synthesis technology, the company has completed the proof of principle and the prototype of desktop high-throughput DNA synthesizer, as well as providing primer synthesis, gene synthesis, subcloning, point mutation, strain library preparation and other services for biological companies and research institutes.

## Funding rounds

- Series A, Jan 22, 2026 — Leader Venture Capital, Zhonggao Capital
- Angel, May 5, 2022 — Qiming Venture Partners, Frees Fund, Neux Capital
- Angel, Jul 20, 2021 — Frees Fund, Next Capital

## Investors

- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Angel
- Next Capital — Angel
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Angel
- Neux Capital — Angel
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series A
- Zhonggao Capital (https://capitalatlas.ai/funds/zhonggao-capital) — Series A